Liver-Biliary-Pancreatic Center, Carolinas HealthCare System, Charlotte, NC 28203, USA.
Clin Chim Acta. 2011 Nov 20;412(23-24):2241-7. doi: 10.1016/j.cca.2011.08.014. Epub 2011 Aug 16.
The measurement of serum hepcidin, a peptide hormone that regulates iron metabolism, is clinically important to the understanding of iron homeostasis in health and disease. To date, the quantification of serum hepcidin levels by conventional immunological detection methods has proven problematic due to challenges in obtaining high quality antibodies which demonstrate good reproducibility. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) has been employed recently for more sensitive quantification of hepcidin; however, this method has high background levels and therefore less than optimal specificity.
In order to increase the specificity of the mass spectrometry based assay, we developed a robust, ultra-performance liquid-chromatography-tandem mass spectrometry (UPLC-MS/MS) protocol using multiple selected reaction monitoring (mSRM) for quantification of hepcidin levels in urine and serum of human subjects. With this assay, we assessed levels of hepcidin before and for up to 8 h after oral ingestion of ferrous sulfate in ten adult human subjects without known disease.
The linear response of hepcidin quantitation on each instrument was measured, and the correlation coefficients of these calibrations were r(2)=0.9512±0.0202 (n=5) for urine and r(2)=0.9709±0.0291 (n=5) for serum [r(2)=mean±SD]. Compared to baseline, the levels of urinary hepcidin between 2-4 h and 4-8 h of both women and men showed significant increases with p<0.05 and p<0.001, respectively. The levels of serum hepcidin between 4 h and 8 h in both women and men showed significant increases, compared with baseline values, with both p<0.01. Interestingly, we also observed some degree of oscillation of levels, occurring at later time points.
We have developed and validated a new method for measuring hepcidin concentrations in human serum and urine and used it to demonstrate early increases with iron supplement in both urinary and serum levels of hepcidin, which return to baseline levels, except in urine samples from men.
血清铁调素是一种调节铁代谢的肽激素,其测量对于理解健康和疾病中的铁稳态具有重要的临床意义。迄今为止,由于难以获得具有良好重现性的高质量抗体,常规免疫检测方法对血清铁调素水平的定量检测证明存在问题。基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF)最近已被用于更敏感地定量铁调素;然而,这种方法的背景水平较高,因此特异性较差。
为了提高基于质谱的测定的特异性,我们开发了一种稳健的超高效液相色谱-串联质谱(UPLC-MS/MS)协议,使用多个选择反应监测(mSRM)来定量人尿液和血清中的铁调素水平。使用该测定法,我们评估了 10 名无已知疾病的成年人类受试者在口服硫酸亚铁前后长达 8 小时内铁调素的水平。
测量了铁调素定量的仪器线性响应,这些校准的相关系数分别为尿液 r(2)=0.9512±0.0202(n=5)和血清 r(2)=0.9709±0.0291(n=5)[r(2)=平均值±SD]。与基线相比,女性和男性的尿液中,2-4 小时和 4-8 小时之间的铁调素水平均显著增加,p<0.05 和 p<0.001。女性和男性的血清铁调素水平在 4 小时至 8 小时之间与基线值相比均显著增加,p<0.01。有趣的是,我们还观察到在稍后的时间点发生了一定程度的水平波动。
我们已经开发并验证了一种用于测量人血清和尿液中铁调素浓度的新方法,并使用它来证明在铁补充剂后,无论是在尿液还是血清铁调素水平,都出现了早期增加,除了男性的尿液样本外,这些水平都恢复到基线水平。